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Summary 
Two forms of genetic instability have been described in colorectal cancer: chromosomal instability, 
characterized by structural and numerical chromosomal abnormalities and associated to aneu­
ploidy; and microsatellite instability, characterized by a defi ciency in the mismatch repair system 
that leads to slippage in microsatellites and is associated to euploidy. Thirteen colorectal cancer 
sample DNAs were analyzed after colectomy. High­resolution genome­wide DNA copy number 
and Single Nucleotide Polimorphism genotyping analysis was performed by Affymetrix SNP 
6.0 arrays that interrogates 906,600 single nucleotide polymorphisms and 945,826 copy number 
probes. We implemented this analysis as part of a routine procedure that includes the sampling 
of fresh tissue from the tumor mass without affecting the subsequent standard histopathologi­
cal procedure. The novel molecular technology allows the determination of a genome­wide 
molecular karyotype using only 500 ng of high­quality tumor DNA; it distinguishes the two 
main types of genomic instability, discriminating between chromosomal instability positive 
and negative tumors. It also detects loss of heterozygosity (LOH) regions, called copy neu­
tral–LOH. Tumor­associated copy neutral­LOH regions may play a pivotal role in oncogenesis 
when they determine duplications of either activating or loss of function gene mutation. We 
observed recurrent gains of chromosomes 2, 7, 8q, 9, 12, 13, 20 and losses of chromosomes 4, 5, 
8p, 15, 17p, 18, 22, and Y, in agreement with previous cytogenetic studies. The use of such sam­
pling procedure could stimulate the routine detection of point mutations in specifi c genes, thus 
avoiding subsequent sectioning of formalin­fi xed and paraffi n­embedded samples.
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Introduction
Colorectal cancer (CRC) affects over 1 million people each year, accounting for 9% 
of all new cancer cases worldwide. It is the fourth most common cancer in men and 
the third most common cancer in women (Poweret al., 2009). CRC was a disease prima­
rily observed in longstanding developed nations, whose populations typically exhibit 
risk factors for colorectal cancer, as obesity, a diet low in fruits and vegetables, physical 
inactivity, and smoking. However, in recent years, high CRC rates have been reported 
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also in newly developed countries. Screening can reduce the mortality associated with 
the disease, but the participation rates are still suboptimal (Center et al., 2009). 
It is well­known that at least two forms of genetic instability have been observed 
in CRC: chromosomal instability (CIN), that is present in 85% cases and is characterized 
by structural and numerical chromosomal abnormalities (aneuploidy); and microsatel-
lite instability (MSI), characterized by a deficiency of the mismatch repair system that 
leads to slippage in microsatellites, and associated to a normal or quasi­normal kary­
otype (euploidy). The latter instability has been found to be associated with heredi­
tary non­polyposis colorectal cancer (HNPCC) that involves mutation of the human 
mismatch repair genes hMSH2 and hMLH1 as well as many sporadic colon cancers. 
It is also clear that such molecular classification has a clinical impact both in prognos­
tic and therapeutic terms. The prognostic value of CIN and MSI has been subject of 
large meta­analyses which established that patients with CIN+ disease have a poorer 
prognosis (hazard ratio for death = 1.45) and patients with MSI+ CRC have a bet­
ter prognosis (hazard ratio = 0.65) (Walther et al., 2008; Popat et al., 2005). Moreo­
ver, several reports have suggested that the efficacy of adjuvant chemotherapy with 
5­fluorouracil in colorectal cancer depends on the mismatch repair status and it has 
also been described a possible detrimental effect of adjuvant 5­FU therapy in loco­
regional MSI+ colorectal cancer (Ribic et al. 2003; Watanabe et al. 2006; Jover et al. 
2009). Finally, several of the chromosomal abnormalities described in CIN+ colorec­
tal cancer may have an important prognostic and clinical impact. Nowadays there 
is still a substantial delay between novel molecular insights and established clinical 
practice. However, recent advances in molecular cytogenetics techniques are likely 
to introduce a revolution in the field (Sheffer et al. 2009). In particular, high resolu­
tion genomic array allows the determination of an accurate genome­wide molecular 
karyotype using only 500 ng of DNA extracted from the tumor mass after colectomy. 
However, the need of high­quality DNA does not allow the use of formalin­fixed and 
paraffin­embedded tissue for this type of analysis. Therefore, in order to exploit the 
advantages provided by novel molecular technologies, it is necessary to adopt some 
minor changes in the routine procedures for tumor sampling and sample storage.
In the present paper we report representative examples of results obtained from 
CIN+ and MSI+ colorectal cancer using last generation photolitographic DNA arrays 
and suggest a protocol for tumor sampling and pathological report.
Materials and Methods
Colorectal cancer tissue sampling for molecular biology after colectomy
The resected colon (Fig. 1) was washed with physiological solution, put it in 
a sterile kidney dish and cut in the longitudinal direction of the intestine to expose 
the lumen. The lumen was washed with physiological solution and two samples of 
tumor tissue (about 100 mg each) were taken in two different points of the tumor 
mass. Samples should fit the following requirements: a) they must derive from the 
principal tumor mass; b) they must be far from the area of transition between normal 
mucosa and tumor; c) they must be taken on the luminal surface of the tumor (<0.3 
cm in depth); d) they must be far away from each other; e) they must not be part of 
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necrotic or suppurative inflamed areas. A sample of normal mucosa was also taken at 
least 3 cm far from the border of tumor mass. Samples were transferred to microtubes 
and immediately carried to the laboratory in a pre­refrigerated LabTop Cooler and 
stored in a ­80°C freezer.
After tissue sampling, the excised colon was fixed in 40% formalin; the tissue was 
then embedded in paraffin for histopathological examination. Microscopic examina­
tion allowed a rough estimation of the fraction of tumor cells in the areas close to the 
tissue sampled for molecular biology.
Tumor samples and genomic DNA extraction
Thirteen colorectal cancer samples were analyzed after colectomy. Six cases were 
assigned at the pathological stage T3N0, six at T3N1, and one at T4N0. 
Genomic DNA (gDNA) was extracted using the QIAamp DNA tissue Mini Kit. 
The concentration and the quality of the DNA was determined using a ND­1000 spec­
trophotometer (NanoDrop, Thermo Scientific, Waltham, MA).
High-resolution genome-wide DNA copy number and SNP genotyping analysis
High­resolution genome­wide DNA copy number and Single Nucleotide Polimor­
phism (SNP) genotyping analysis was performed according to the protocol supplied 
by the manufacturer (Affymetrix, Santa Clara, CA) for Affymetrix SNP 6.0 arrays that 
interrogates 906,600 SNPs and 945,826 copy number probes (SNP/CNV array). Brief­
ly, 500 ng of gDNA (50 ng/ul) was digested with NspI and StyI restriction enzymes, 
ligated to respectively NspI and StyI adaptors, amplified by polymerase chain reac­
tion (PCR) using a single primer with the TITANIUM DNA Amplification Kit (Clon­
tech Laboratories, Montain View, CA). PCR products were purified with Agencourt 
AMPure® Magnetic Beads (Agencourt Bioscience Corporation, Beverly, MA) and puri­
fied amplicons were fragmented, end­labeled and hybridized to a Genechip Affyme­
trix SNP 6.0 arrays at 50°C for 16­18 hours in a GeneChip® Hybridization Oven 
640 (Affymetrix). After washing and staining in a GeneChip® Fluidics Station 450 
(Affymetrix), the arrays were scanned with a GeneChip® Scanner 3000 7G (Affyme­
trix). Array scanning and data analysis were performed using Affymetrix® “GeneChip 
Operating Software” (GCOS) and “Genotyping Console™” (GTC) version 3.0.1.
Results
The Single Nucleotide Polimorphism (SNP) array technology allowed for a clear 
discrimination of CIN+ and CIN­ tumors (compare Figs. 2A and B). 85% of the ana­
lyzed tumors were CIN+. The average age of patients affected by aneuploid tumors 
was 65.64 + 10.33, while the age of patients affected by euploid tumors was 46.5 + 3.53.
As expected, the euploid tumor in Fig. 2B showed a high degree of microsatel­
lite instability (MSI+), as detected by a specific PCR test according to NHI guidelines 
(Dietmaier et al. 1997).
The technology used in the present study performs also the genotyping analy­
sis of almost 900.000 SNPs and allowed us the detection of loss of heterozygos­
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ity (LOH) regions that occurs without concurrent changes in the gene copy number. 
Such defects, called copy neutral (CN) ­LOH, are attributed to mitotic recombination 
occurring in somatic cells or to abnormalities following repair of DNA double­strand 
breaks. Tumor­associated CN­LOH regions may play a pivotal role in oncogenesis 
when they determine either duplications of activating genes or loss of function muta­
tions.
Indeed, several chromosomal abnormalities were detected in CIN+ tumors in 
agreement with a previous report (Sheffer et al. 2009). An average (+SD) of 13 (±6) 
chromosomal abnormalities (gain, loss or CN­LOH) were detected in tumors at stage 
T3N0, 18 (±2) at stage T3N1 or T4.
An example of a report of all chromosomal abnormalites detected by SNP array in 
the same case of Fig. 2A is reported in Table I.
Discussion
In the present work we report the ability of recent molecular cytogenetic tech­
niques, based on SNP DNA arrays, to distinguish the two main types of genomic 
instability in CRC (CIN and MSI) and describe a routine procedure that allows the 
sampling of fresh tissue from the tumor mass without affecting the following stand­
ard histopathological procedure. While efficient molecular tests for detection of MSI 
are already available (Dietmaier et al., 1997), in routine analysis CIN has been mainly 
supposed indirectly by exclusion of MSI. The availability of such techniques and their 
wide application should clarify the existence of CIN­ and MSI­ tumors and provide 
a large amount of information on their molecular abnormalities. Among the more 
frequent chromosomal abnormalities in CIN+ tumors, we observed gain of chromo­
somes 2, 7, 8q, 9, 12, 13, 20 and loss of chromosomes 4, 5, 8p, 15, 17p, 18, 22, and Y.
Moreover, recent advances in analysis of SNP­array data allow for a quantifica­
tion of tumor and normal cell fraction in the case of CIN+ tumors (Assie et al., 2008; 
Goransson et al., 2009). Indeed, even in the presence of a contaminant fraction of nor­
mal cells up to 50%, SNP arrays were sensitive enough to detect the main chromo­
somal abnormalities.
Another advantages of such standard procedure for tissue sampling is the pos­
sibility to extract undegraded RNA from the same frozen samples used for DNA 
extraction, thus allowing the preparation of a DNA and RNA Bank available for 
genomic and transcriptomic studies.
Finally, the use of such a sampling procedure dedicated to molecular biology 
analysis could stimulate the routine detection of point mutations in specific genes, 
thus avoiding subsequent sectioning of formalin­fixed and paraffin­embedded sam­
ples and allowing integration of information on point mutations with that derived by 
genome­wide analysis of chromosomal abnormalities and gene expression changes.
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(copy number in 
brackets)
Loss
(copy number in 
brackets)
CN­LOH




5 CN­LOH whole chr.
6 whole chr. (1)
7 whole (3)




14 cen­q11.2 (3­5) CN­LOH q11.2­qtel
17 p(1) CN­LOH q
18 whole chr (1)
20 q (3­4) p(1)
Table I – Report of chromosomal abnormalites detected by SNP array analysis in CIN+ colorectal cancer
Fig. 1 – Surgical specimen of colectomy (removal of the colon) showing a cancer.
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Fig. 2 – Overview of copy number changes in CIN+ (A) and CIN- MSI+ (B) colorectal cancer. Gains and losses 
are represented on chromosome ideograms by blue and red triangles respectively (karyoview by Affymetrix® 
Genotyping Console 3.0.1).
